1. Sistemik Antimon ile Tedavi Edilen Kutanöz Leishmaniasis Tanılı Hastaların Klinik Özellikleri ve Tedavi Yanıtları.
- Author
-
DONİ, Nebiye YENTUR and AN, İsa
- Subjects
- *
ANTIPROTOZOAL agents , *LEISHMANIASIS , *RETROSPECTIVE studies , *ACQUISITION of data , *TREATMENT effectiveness , *INTRAMUSCULAR injections , *COMPARATIVE studies , *PROTOZOAN diseases , *SYMPTOMS , *MEDICAL records , *DESCRIPTIVE statistics , *EVALUATION - Abstract
Background: Cutaneous leishmaniasis (CL) is a skin disease caused by protozoan parasites belonging to the Leishmania genus. The most commonly preferred treatment option for CL treatment is pentavalent antimony compounds. The aim of this study is to investigate the clinical characteristics and treatment responses of patients diagnosed with CL treated with systemic antimony. Materials and Methods: This retrospective study included 52 patients diagnosed with CL and treated with systemic antimony in our skin and venereal diseases clinic between May 2018 and May 2020. The clinical and demographic characteristics recorded in the patients' files were examined. Systemic antimony (intramuscular meglumine antimonate (IM MA)) was administered Results: 30 (57.7%) of the patients in our study w ere female a nd 22 (42.3%) were male. The average age of the patients was 26.5±14.23 years. Lesions were most frequently located in the facial region, and noduloulcerative type lesions were most frequently seen. The diagnosis of CL was made by observing amastigotes in the cutaneous smear in 48 (92.3%) patients and in the histopathological examination of the lesioned skin in 4 (7.7%) patients. When the patients receiving IM MA treatment were evaluated at the 12th week in terms of treatment response, complete clinical recovery of the lesions was observed in 50 (96.1%) patients and partial clinical improvement was observed in 2 (3.9%) patients. Conclusions: As a result, the data in our study were similar to the clinical and demographic data on CL previously published in our country. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF